MOTS-c
A 16-amino-acid peptide encoded within the mitochondrial genome — specifically the 12S ribosomal RNA gene — rather than the nuclear genome, placing it within the emerging class of mitochondria-derived peptides (MDPs). Investigated in preclinical models for metabolic regulation, insulin sensitivity, and physical performance in the context of aging. As of mid-2026, the evidence base is entirely preclinical; no peer-reviewed first-in-human trial of native MOTS-c has been published, and the compound should be understood as early-stage research.
Side effects & risks
MOTS-c has not been evaluated in any peer-reviewed clinical trial in humans. As of mid-2026, no published human data exists for native MOTS-c, and no comprehensive human safety profile exists. The risk profile for community-style administration is, in practical terms, unknown.
In the preclinical literature — predominantly rodent models — acute toxicity was not observed at the doses studied. Reynolds et al. (2021, Nature Communications; PMID 33473109) reported no adverse events in the mouse studies forming part of that investigation. The absence of observed toxicity in rodent models is not equivalent to demonstrated human safety.
As of mid-2026, no peer-reviewed first-in-human study of native MOTS-c has been published. The only human-adjacent safety signal comes from CohBar's CB4211 analogue programme, presented at AASLD 2021 in conference-poster form only — not peer-reviewed. CB4211 is structurally distinct from native MOTS-c, and its safety profile cannot be directly extrapolated to native MOTS-c. The safety profile of native MOTS-c in humans is, in practical terms, uncharacterised.
Because MOTS-c is a mitochondrially encoded peptide with proposed roles in metabolism and stress signalling, theoretical concerns include effects on mitochondrial bioenergetics and nuclear gene regulation. The extent to which exogenous MOTS-c administration affects endogenous MOTS-c levels or cellular metabolic programmes has not been characterised in humans.
Drug interactions have not been studied. Injection-site reactions consistent with subcutaneous peptide administration are theoretically expected but have not been systematically reported.
MOTS-c is not approved for human therapeutic use in any major regulatory jurisdiction. Individuals obtaining it as a research chemical assume an undetermined risk profile.
Evidence summary
Latest studies
Mitochondria-derived peptide hydrogel augments mitochondrial transplantation for promoting cardiac repair via macrophage metabolic reprogramming.
Donor mitochondria are extremely fragile once isolated, which has held back mitochondrial transplantation after heart attacks. Researchers linked MOTS-c to a self-assembling peptide to build a hydrogel that kept isolated mitochondria functional for at least eight hours and helped immune cells take them up. In rats with induced heart attacks, the combined material shifted macrophages away from an inflammatory state and improved cardiac function.
Correction: Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction.
A publisher's correction to a previously published study on reduced MOTS-c levels in women with polycystic ovary syndrome. It contains no new findings.
Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review.
This systematic review screened 435 records and pooled nine studies asking whether physical exercise changes circulating levels of mitochondria-derived peptides such as humanin and MOTS-c. Most of the included studies reported a trend toward higher peptide levels after exercise, alongside markers of better insulin sensitivity and cellular energy metabolism. The authors are explicit that the evidence base is small and that populations, exercise protocols and study designs varied substantially.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“NAD+, MOTS-C and 5-Amino-1MQ: What Happens When You Combine Three Metabolic Research Compounds?”
An explainer-style thread exploring the rationale for combining NAD+, MOTS-c, and 5-amino-1MQ as a metabolic stack; of the three, only MOTS-c is a tracked peptide, and the framing is educational rather than experiential.
“MOTS-C is my favorite pep for energy. What's yours?”
A community favorites thread in which the poster names MOTS-c as their top pick for perceived energy effects and invites others to share theirs, offering a window into which peptides users associate with energy.
“MOTS-c — what’s your experience with it?”
A thread soliciting firsthand experiences with MOTS-c, the mitochondrial-derived peptide, gathering community reports on how users have incorporated it and what effects they associate with it.
“Mots-c do's and dont's?”
A question thread asking the community for practical do's and don'ts around MOTS-c use, covering how users approach dosing, timing, and common pitfalls in reported protocols.
“8 weeks on reta + mots c + a little mt1 😎”
An eight-week personal log of a combined regimen of retatrutide, MOTS-c, and a small amount of melanotan-1, shared as a progress report on a multi-compound stack popular in body-recomposition circles.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| Metabolic support (community-reported) | SC injection | 5–10 mg | 2–3× weekly | Not established |
Frequently asked questions
- What makes MOTS-c unusual compared with other research peptides?
- MOTS-c is encoded within the mitochondrial genome — specifically the 12S ribosomal RNA gene — rather than the nuclear genome. This makes it part of an emerging class of mitochondria-derived peptides (MDPs). Its proposed ability to translocate to the nucleus and regulate gene expression despite its mitochondrial origin is mechanistically distinctive and has drawn significant research interest in ageing biology.
- Has MOTS-c been tested in humans?
- As of mid-2026, no peer-reviewed first-in-human study of native MOTS-c has been published. The only human-adjacent clinical data is for CB4211, a structurally modified MOTS-c analogue developed by CohBar Inc., reported in conference-poster form at AASLD 2021 — not peer-reviewed. Subcutaneous bioavailability and safety of native MOTS-c in humans remain uncharacterised in the published scientific literature. No phase II or III trials addressing metabolic or performance endpoints for native MOTS-c have been published.
- What is the proposed mechanism behind MOTS-c's metabolic effects?
- The primary hypothesis is that MOTS-c inhibits de novo purine synthesis and the tetrahydrofolate cycle under metabolic stress, leading to AICAR accumulation. AICAR is a natural AMPK activator; AMPK promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. This pathway was characterised in the founding paper by Lee et al. (2015, Cell Metabolism) in rodent models. Whether the same mechanistic cascade operates in humans from exogenously administered synthetic MOTS-c has not been established in clinical studies.
- Is MOTS-c an 'exercise mimetic'?
- Reynolds et al. (2021, Nature Communications) showed that circulating MOTS-c rises after acute exercise in mice and that exogenous MOTS-c improved physical performance and metabolic parameters in aged mice, in part recapitulating exercise-induced adaptations. This is the primary basis for the 'exercise mimetic' characterisation in community discussions. The translation of these rodent findings to humans has not been tested in controlled trials, and the framing should be understood as a hypothesis rather than an established effect.
- Is MOTS-c legal to buy or use?
- MOTS-c is not approved for human therapeutic use in the United States, Australia, Canada, the UK, or the EU. In most jurisdictions it is sold as a research chemical. Regulatory status varies by country and is subject to change; verify current status with a qualified legal or clinical professional.